Topic Archives: Briefing.com

Comments

  • Avatar

    Setting aside how most Gumshoers regard Altucher, SSTI had a wonderful price run up in Jan 2019 and then based/traded si...

  • Avatar

    Travis, Here is a summary of IIPR's recent activity (2/13/19) from Briefing.com which (as it seems to me) is causing the...

  • Travis Johnson, Stock Gumshoe

    I don't like Yahoo Finance much anymore, they no longer collect much useful information outside of the basic fundamental...

  • Travis Johnson, Stock Gumshoe

    My favorite summary sources for that kind of basic info are YCharts and Briefing.com, though neither is free....

  • Avatar

    FYI, I saw a news brief dated 1/9/2018 stating "BIVV ...will acquire all shares in FIVE Inc, making it a subsidiary of t...

  • Travis Johnson, Stock Gumshoe

    Another note about the focus on this sector, from briefing.com this morning: Qualcomm Incorporated (QCOM...

  • Avatar

    $SNNA No Position From Briefing.com STORY STOCKS® | Updated: 21-Aug-17 | Archive | Add to Column Alerts Brief...

  • Avatar

    $ AFMD long From Briefing.com Exelixis (EXEL) initiated with Buy and $33 tgt, Affimed Therapeutics (AFMD) with Buy...

  • Avatar

    $SCYX Briefing.com in-play article: --The first oral presentation (#OS0846) described new data from a multicenter ...

  • Avatar

    $AKAO: -How much weight should one place on financial analyst opinions on stock recommendations? IMO, this provides th...

  • Travis Johnson, Stock Gumshoe

    Here's the first really optimistic growth forecast I've seen for STM lately, based largely on the fact that they've appa...

  • Travis Johnson, Stock Gumshoe

    Update today from Briefing.com: Himax Tech target raised to $14 at Craig Hallum -- It’s looking more an...

  • Avatar

    Actinum Pharma to provide clinical update on Actimab-A at upcoming 2015 ASCO annual meeting on Sunday, May 31 Briefing....

  • Avatar

    Also Robert Re; $NBY Briefing.com is reporting that shares were halted at 3:43PM because of good news. http://finance.y...

  • Avatar

    Akebia Therapeutics misses by $0.02 Briefing.com - 7:05 AM ET, 11/10/2014 Reports Q3 (Sep) loss of $0.47 per share...

  • Avatar

    YES!!!! Durata Therapeutics to be acquired by Actavis (ACT) for $23.00/share in cash, or ~$675 million in the aggregate...

  • This site and Stock Gumshoe publications and authors do not offer individual financial, investment, medical or other advice. Nothing on this site should ever be considered to be personal advice, research or an invitation to buy or sell any securities. We also make mistakes and bad decisions sometimes, and our reasoning or data should be checked against trusted sources before they inform your investing decisions. Choices regarding how to invest your money or otherwise manage your life or finances are yours, we share only our analysis and opinion and all authors or commenters are individually responsible for the words and opinions they share here. Please read our important disclaimers and policies. Stock Gumshoe is supported by subscribers and by sponsors and advertisers. Stock Gumshoe's employee authors will disclose holdings in any stock covered at time of publication and will not trade in any stocks written about for at least three days after publication. Please see below for complete disclosure, disclaimer and policy information.

    Connect with Travis

    website designed by Gravity Switch